inflection_biosciences_logo_2015 transpa
  • ABOUT US

    • TEAM
    • DIRECTORS
    • ADVISORS
    • CAREERS
  • WHAT WE DO

    • PIPELINE
    • TECHNOLOGY
    • IBL-101
    • IBL-202
    • AUM302
  • NEWS

    • PRESS RELEASES
    • IN THE NEWS
    • PUBLICATIONS
  • PARTNERSHIPS

    • IN-LICENSING
    • OUT-LICENSING
  • CONTACT US

  • More

    Use tab to navigate through the menu items.

    Developing Innovative Therapeutics

    Our Company

    Inflection Biosciences is developing small molecule therapeutics for the treatment of cancer, autoimmune and inflammatory disease. The pipeline comprises of IBL-101, an oral, pan-PIM kinase inhibitor in development for autoimmune and inflammatory disease,  IBL-202, selected from a series of unique dual mechanism kinase inhibitors and AUM302 (formerly IBL-302), partnered with AUM Biosciences.

    Read More

    What We Do

     

    LEARN MORE

    Pipeline

     

    EXPLORE

    Partnerships

    LEARN MORE

    NEWS

    Inflection Biosciences
    • May 30

    Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence

    ESCHBORN, Germany, May 30, 2022 Innoplexus, a global leader in AI-based drug discovery and development, and Inflection Biosciences Ltd.,...
    Inflection Biosciences
    • May 27

    Inflection Biosciences Announces Expansion of Research into Autoimmune and Inflammatory Disease

    Expands Advisory Panel with Immunology and Rheumatology Expertise Dublin, Ireland, May 27, 2022 Inflection Biosciences Ltd, a company...
    Inflection Biosciences
    • Nov 11, 2021

    Inflection Biosciences Announces Publication on Discovery of AUM302 in ACS Medicinal Chemistry

    Dublin, Ireland, November 10, 2021 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer,...
    View More >>
    inflection_biosciences_logo_2015%20trans

    Disclaimer   Copyright    Privacy Policy

    OUR COMPANY

    TEAM

    DIRECTORS

    ADVISORS

    CAREERS

    WHAT WE DO

    PIPELINE

    TECHNOLOGY

    IBL-101

    IBL-202
    AUM302

    NEWS

    PRESS RELEASES

    IN THE NEWS

    PUBLICATIONS

    PARTNERSHIPS

    IN-LICENSING

    OUT-LICENSING

    CONTACT US

    4 Logos with Text.png

    FOLLOW US

    • Twitter
    • LinkedIn Social Icon

    Copyright © 2012-2020 Inflection Biosciences, Inc. All Rights Reserved

    EITH_EU_White_V_ .png